Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells

Y. Q. Liu, E. Kyle, S. Patel, Franck Housseau, F. Hakim, R. Lieberman, M. Pins, M. V. Blagosklonny, R. C. Bergan

Research output: Contribution to journalArticle

Abstract

Preclinical models for the identification of prostate cancer chemoprevention agents are lacking. Based upon the notion that clinically useful chemoprevention agents should exhibit selective activity against early stage disease, studies were undertaken to assess whether chemoprevention agents selectively inhibited the growth of early stage prostate cancer, as compared to late stage cancer. First, a series of cell and molecular studies were performed, which, when taken together, validated the use of a panel of prostate cell lines as a model of the different stages of carcinogenesis. Next, therapeutic responsiveness to ten different cytotoxic or chemoprevention agents was evaluated. Chemoprevention agents exhibited selective activity against normal and early transformed prostate tissue, whereas cytotoxic agents were non-specific. Selective activity against early versus advanced prostate cancer cells is identified as a potential screening method for chemoprevention agents.

Original languageEnglish (US)
Pages (from-to)81-91
Number of pages11
JournalProstate Cancer and Prostatic Diseases
Volume4
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Chemoprevention
Prostatic Neoplasms
Prostate
Cytotoxins
Carcinogenesis
Cell Line
Growth
Neoplasms

Keywords

  • Cell growth
  • Chemoprevention
  • Preclinical models
  • Prostate cancer
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. / Liu, Y. Q.; Kyle, E.; Patel, S.; Housseau, Franck; Hakim, F.; Lieberman, R.; Pins, M.; Blagosklonny, M. V.; Bergan, R. C.

In: Prostate Cancer and Prostatic Diseases, Vol. 4, No. 2, 2001, p. 81-91.

Research output: Contribution to journalArticle

Liu, YQ, Kyle, E, Patel, S, Housseau, F, Hakim, F, Lieberman, R, Pins, M, Blagosklonny, MV & Bergan, RC 2001, 'Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells', Prostate Cancer and Prostatic Diseases, vol. 4, no. 2, pp. 81-91. https://doi.org/10.1038/sj.pcan.4500506
Liu, Y. Q. ; Kyle, E. ; Patel, S. ; Housseau, Franck ; Hakim, F. ; Lieberman, R. ; Pins, M. ; Blagosklonny, M. V. ; Bergan, R. C. / Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. In: Prostate Cancer and Prostatic Diseases. 2001 ; Vol. 4, No. 2. pp. 81-91.
@article{d7d3a8934df047df843c6d105615aed2,
title = "Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells",
abstract = "Preclinical models for the identification of prostate cancer chemoprevention agents are lacking. Based upon the notion that clinically useful chemoprevention agents should exhibit selective activity against early stage disease, studies were undertaken to assess whether chemoprevention agents selectively inhibited the growth of early stage prostate cancer, as compared to late stage cancer. First, a series of cell and molecular studies were performed, which, when taken together, validated the use of a panel of prostate cell lines as a model of the different stages of carcinogenesis. Next, therapeutic responsiveness to ten different cytotoxic or chemoprevention agents was evaluated. Chemoprevention agents exhibited selective activity against normal and early transformed prostate tissue, whereas cytotoxic agents were non-specific. Selective activity against early versus advanced prostate cancer cells is identified as a potential screening method for chemoprevention agents.",
keywords = "Cell growth, Chemoprevention, Preclinical models, Prostate cancer, Treatment",
author = "Liu, {Y. Q.} and E. Kyle and S. Patel and Franck Housseau and F. Hakim and R. Lieberman and M. Pins and Blagosklonny, {M. V.} and Bergan, {R. C.}",
year = "2001",
doi = "10.1038/sj.pcan.4500506",
language = "English (US)",
volume = "4",
pages = "81--91",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells

AU - Liu, Y. Q.

AU - Kyle, E.

AU - Patel, S.

AU - Housseau, Franck

AU - Hakim, F.

AU - Lieberman, R.

AU - Pins, M.

AU - Blagosklonny, M. V.

AU - Bergan, R. C.

PY - 2001

Y1 - 2001

N2 - Preclinical models for the identification of prostate cancer chemoprevention agents are lacking. Based upon the notion that clinically useful chemoprevention agents should exhibit selective activity against early stage disease, studies were undertaken to assess whether chemoprevention agents selectively inhibited the growth of early stage prostate cancer, as compared to late stage cancer. First, a series of cell and molecular studies were performed, which, when taken together, validated the use of a panel of prostate cell lines as a model of the different stages of carcinogenesis. Next, therapeutic responsiveness to ten different cytotoxic or chemoprevention agents was evaluated. Chemoprevention agents exhibited selective activity against normal and early transformed prostate tissue, whereas cytotoxic agents were non-specific. Selective activity against early versus advanced prostate cancer cells is identified as a potential screening method for chemoprevention agents.

AB - Preclinical models for the identification of prostate cancer chemoprevention agents are lacking. Based upon the notion that clinically useful chemoprevention agents should exhibit selective activity against early stage disease, studies were undertaken to assess whether chemoprevention agents selectively inhibited the growth of early stage prostate cancer, as compared to late stage cancer. First, a series of cell and molecular studies were performed, which, when taken together, validated the use of a panel of prostate cell lines as a model of the different stages of carcinogenesis. Next, therapeutic responsiveness to ten different cytotoxic or chemoprevention agents was evaluated. Chemoprevention agents exhibited selective activity against normal and early transformed prostate tissue, whereas cytotoxic agents were non-specific. Selective activity against early versus advanced prostate cancer cells is identified as a potential screening method for chemoprevention agents.

KW - Cell growth

KW - Chemoprevention

KW - Preclinical models

KW - Prostate cancer

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0034947013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034947013&partnerID=8YFLogxK

U2 - 10.1038/sj.pcan.4500506

DO - 10.1038/sj.pcan.4500506

M3 - Article

AN - SCOPUS:0034947013

VL - 4

SP - 81

EP - 91

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 2

ER -